clinical trial · NCT06314529
Long-term Follow-up Study of BHC001 for TDT
Bioray Laboratories·—·recruiting·n = 6
Thalassemia, BetaAssessments
brief summary
Observe long-term safety risk and long-term efficacy after intravenous infusion of BHC001 in TDT subjects.
started
Dec 14, 2022
primary completion
Dec 10, 2036
completion
May 10, 2037
last updated
Mar 18, 2024
detailed description
Observe long-term delayed safety risks such as emerging neoplasms, emerging haematological disorders, and long-term efficacy after intravenous infusion of BHC001 in TDT subjects.
official title
Long-term Follow-up Study of BHC001 in the Treatment of Transfusion-dependent β-thalassemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol